Nerandomilast attenuates idiopathic inflammatory myopathy-associated interstitial lung disease via inhibiting proliferation and differentiation of B cells.

In the lungs of IIM-ILD model mice, flow cytometry identified a significant elevation in the percentage of CD19 + B cells, which showed a decreasing trend upon Nerandomilast treatment, although the high-dose Nerandomilast group did not reach statistical significance ( Figures 6C, D ).

also in 47,180 other papers

Notably, high-dose Nerandomilast showed improvement in pulmonary function parameters but did not reach statistical significance, suggesting that in this IIM-ILD model, the low dose may have reached a pharmacodynamic plateau for maximal pulmonary function improvement, and the high-dose group exhibited greater data variability, which may also affect statistical significance.

also in 111,027 other papers